Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.59 |
| ▸ | ECE1 | P42892 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 3/20 | 0.56 |
| ▸ | LGMN | Q99538 | 4/20 | 0.54 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.49 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.49 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.49 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20677213 | 1.00 | MME (0.59) | MMEECE1CTSKLGMNPSMB1 | |
| SCHEMBL19384748 | 1.00 | MME (0.59) | MMEECE1CTSKLGMNPSMB1 | |
| SCHEMBL20263591 | 1.00 | MME (0.59) | MMEECE1CTSKLGMNPSMB1 | |
| SCHEMBL14371944 | 1.00 | MME (0.59) | MMEECE1CTSKLGMNPSMB1 | |
| SCHEMBL28819863 | 0.99 | MME (0.60) | MMEECE1CTSKLGMNPSMB1 | |
| SCHEMBL28645693 | 0.99 | MME (0.60) | MMEECE1CTSKLGMNPSMB1 | |
| SCHEMBL21523352 | 0.92 | MME (0.55) | MMEECE1CTSKLGMNPSMB1 | |
| SCHEMBL20287884 | 0.92 | MME (0.52) | MMEECE1CTSKLGMNPSMB1 | |
| SCHEMBL21523353 | 0.92 | MME (0.55) | MMEECE1CTSKLGMNPSMB1 | |
| SCHEMBL20323161 | 0.92 | MME (0.55) | MMEECE1CTSKLGMNPSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039341-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039341-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | KIFC1, KIF2C, KIF5B | MME 2837/4885ECE1 3167/4885CTSK 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.